PRODUCTGENOTROPIN / NGENLA

Pfizer’s growth hormone franchise consists of two different formulations, namely Genotropin (somatropin) which is once daily, and Ngenla (somatrogon) which is once weekly. Ngenla was first approved in the EU and Japan in 2022, followed by the US in 2023, while Genotropin has been marketed by Pfizer since 2003. Both products are indicated to treat pediatric growth hormone deficiency – Genotropin is also labeled to treat Prader-Willi Syndrome, Small for Gestational Age, Turner Syndrome, Idiopathic Short Stature and adult growth hormone deficiency.

Background

OPKO issued to HCRx, a limited recourse loan with payments that reference OPKO’s profit share economics. OPKO sought to raise non-dilutive capital and gain financial flexibility to advance their research and development activities, as well as creating optionality to refine their capital structure.